Health News
Latest health news and updates
Total: 54
China’s Fountain of Youth: The Dangerous Rise of the Underground Stem Cell Market
China is witnessing a surge in illegal stem cell infusions marketed as high-priced anti-aging treatments, often involving collusion between private firms and public hospital doctors. Despite costs reaching $55,000 per shot, there is no scientific evidence or regulatory approval for these therapies, posing significant health and financial risks to consumers.
Bispecific ADC Combined with PD‑1 Inhibitor Shows Promising Frontline Activity in Extensive‑Stage Small‑Cell Lung Cancer
A phase II trial in China led by Prof. Zhou Caicun reports that the EGFR×HER3 bispecific ADC iza‑bren combined with a domestic PD‑1 inhibitor (Sru‑li) produced a median PFS of 8.2 months and a one‑year OS rate of 85.7% as first‑line therapy for extensive‑stage small‑cell lung cancer. The results are promising compared with historical chemo‑immunotherapy benchmarks but require validation in larger, randomized studies with full safety data.
How China’s Private‑Domain Marketing Industry Uses Fake ‘Medical Experts’ to Sell Overpriced Health Products to Seniors
CCTV‑led reporting exposed a private‑domain marketing network in China that uses paid actors posing as medical experts to sell cheap medicines and supplements at sharply inflated prices to elderly consumers. Video producers, private‑domain operators and contractors create scripted lectures and sell products in closed social‑media channels, prompting likely regulatory scrutiny after the 3·15 consumer‑rights season.
CCTV Spotlight Sinks Credibility of Zhengzhou Biotech as Multiple Patents Rejected
CCTV’s consumer‑rights programme named Zhengzhou Yuanchuang Gene in a probe of overhyped exosome products, and public records show several of the company’s patent applications have been rejected. The development highlights the tension between genuine exosome research and a market of unproven claims, and signals heightened regulatory and reputational risks for small biotech firms in China.
Inside China’s Private‑Domain Sales Machine: Cheap Medicines Repackaged and Sold at Five‑Fold Markups to the Elderly
A 3·15 investigation exposed a private‑domain marketing industry in China that repackages low‑cost medicines and supplements into expensive, persuasive video lectures sold to elderly consumers. The scam hinges on fabricated expert authority and intimate social‑platform channels, yielding markups of up to five times the purchase price and prompting renewed regulatory scrutiny.
Microsoft Rolls Out Copilot Health — An AI Health Hub That Raises Privacy and Regulation Questions
Microsoft announced Copilot Health, a secure health workspace inside its Copilot assistant that aggregates health records, wearable data and medical history to produce personalised insights. The product deepens Microsoft’s push into health tech but raises practical questions about interoperability, clinical validation and regulatory compliance.
From Test Kits to First‑in‑Class Drugs: Hotgen’s Bid to Anchor ‘Healthy China’ in Home‑grown Biotech
Hotgen Biotech is pursuing a dual diagnostics‑and‑innovative‑drug strategy to back China’s Healthy China goals, advancing an antibody for acute myocardial infarction, SGC001, into Phase II. The effort exemplifies China’s broader shift from following foreign pharmaceutical models to developing first‑in‑class domestic innovations, but faces clinical, manufacturing and regulatory hurdles before it can transform national health and global competitiveness.
A Silver Needle for Readiness: How a PLA Acupuncturist Rewrote Military Medicine in the Field
Guan Ling, head of acupuncture at the PLA General Hospital, has developed an anatomy‑informed “structural acupuncture” approach that she and state outlets credit with reducing training injuries and drug use across pilot units. Her work — delivered in deserts, highlands and aboard ships — has been scaled through a large training programme that aims to keep minor injuries treatable at the unit level and protect combat readiness. The initiative highlights the PLA’s pragmatic integration of traditional Chinese medicine into force health protection while raising questions about the need for independent clinical validation.
Russian Team Trains AI to Flag Early Breast Cancer on CT Scans — Promise, Not Proof
A Russian research team has developed an AI neural network that analyses CT scans to mark areas suspicious for early breast cancer and forwards annotated images to doctors. The tool could convert routine CTs into opportunistic screening opportunities, but its clinical value remains unproven pending independent validation, transparency about performance metrics, and resolution of privacy and regulatory issues.
Operating-Theatre Tutelage: How a Visiting Professor Is Building Micro‑Intervention Capacity in Sichuan’s Military Hospital
A visiting professor from a top military hospital has transformed surgical practice at a provincial military hospital in Sichuan by using hands‑on, bedside mentorship to build local capacity in ultrasound‑guided minimally invasive procedures. The programme has reduced referrals to higher centres and instilled a culture of problem‑solving that favours micro‑invasive options when clinically appropriate.
Beijing Outcry After Customer Finds Suspected Parasite Eggs on Tuna at Popular Sushi Chain; Regulators Open Probe
A diner in Beijing alleges they found suspected parasite eggs on tuna served at Sushiro, a Japanese conveyor-belt sushi chain; the Mentougou District Market Supervision Bureau has preserved samples and opened an investigation. The result of laboratory testing and the chain's public response will determine regulatory penalties and reputational damage amid heightened consumer scrutiny of raw seafood safety.
Painless Patch for Immune Cells: Microneedle Device Promises Non‑Invasive Immune Monitoring
A collaboration between The Jackson Laboratory and MIT has produced a microneedle patch that non‑invasively samples immune cells from humans, enabling painless, repeatable collection for laboratory analysis. Published in Nature Biomedical Engineering, the device could reshape immune monitoring in clinical trials, vaccine development and personalised medicine, though validation, regulatory approval and ethical safeguards are still required.